ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ACTU / dividends
KYNB (32) AKTX (37) MCRB (40) COCP (36) ⌘ Pro Terminal β†’

Actuate Therapeutics Inc. (ACTU) Dividend Safety Gauge & 10-Year DRIP Compounder

$0.34 +2.06% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.34

Actuate Therapeutics Inc. (ACTU) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $18.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACTU Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ACTU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Actuate Therapeutics Inc. (NASDAQ: ACTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.34 (+2.06% 1D, market cap $18.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ACTU ranks #609 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ACTU compare to KYNB and AKTX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACTU carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, ACTU leads on earnings multiple (N/A) while ACTU leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACTU?
β–Ό

Per ACTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652935), Actuate Therapeutics Inc. generated $63.0M in revenue (-10.6% YoY), -$22.2M in net income, and -$19.2M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.34 (+0.18%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (6)Whales (5)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
$8 Bull$0 Base$0 Bear
πŸ“¬ FREE ACTU RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ACTU)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY ACTU SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–² #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 33.3 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$0.47+31.9% Next Q
Q2 (-2Q)
40
Grade D$0.62-35.5% Next Q
Q3 (-1Q)
38
Grade E$0.40-15% Next Q
Current
35
Grade D-$0.34-8.5% Hist 90D Ξ±
Trajectory: D (43) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ACTU Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ACTU currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.87) and Max Pain ($0.36) forces dealer call-delta covering toward $8.29.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACTUβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œACTU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACTU)

  • βœ“Walkthrough of ACTU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ACTU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.47%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $0.38H $0.38L $0.34C $0.34VOL 489.5K
RES: $1.04SUP: $0.26SMA50: $0.87SMA200: $2.11
$6.05$4.50$2.95$1.40$-0.15RES $1.04SUP $0.26$0.342026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACTU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ACTU Butterfly Map β†’ + Track ACTU β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -10.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ACTU today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ACTU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACTU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACTU)

Health Care Rank #609 of 1015 βš”οΈ KYNB vs ACTU Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ACTU vs. KYNB, AKTX, MCRB, COCP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Actuate Therapeutics Inc. (ACTU) ranks #609 by composite RQD confidence (35/100, grade D-) and #835 by equity capitalization ($18.4M). Within this direct 5-issuer industry benchmark cohort, ACTU leads on earnings valuation at N/A trailing P/E, while ACTU leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ACTU at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ACTU ACTIVE
Actuate Therapeutics Inc.
D- 35/100 β€” β€” -35.0% +2.06% $18.4M Benchmark Subject
KYNB
Kyntra Bio Inc.
E 32/100 β€” 91.4% -35.0% -2.41% $18.5M /kynb-vs-actu β†’
AKTX
Akari Therapeutics plc ADS
D- 37/100 β€” β€” -35.0% -4.85% $18.8M /aktx-vs-actu β†’
MCRB
Seres Therapeutics Inc.
D- 40/100 β€” β€” -35.0% +3.39% $17.8M /mcrb-vs-actu β†’
COCP
Cocrystal Pharma Inc.
D- 36/100 β€” β€” -35.0% +6.53% $19.2M /cocp-vs-actu β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001652935 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actuate Therapeutics Inc. (ACTU) reported GAAP revenue of $63.0M (-10.6% vs. FY2024 revenue of $70.5M , and -9.9% cumulative change since FY2023) , GAAP net income of -$22.2M, operating cash flow of -$19.2M, and free cash flow of -$19.2M (+12.1% YoY). On the balance sheet, ACTU closed FY2025 with $14.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $63.0M -$22.2M -$19.2M -$19.2M $14.0M β€”
FY2024 (FY) 2024-12-31 $70.5M -$27.3M -$21.8M -$21.8M $9.3M β€”
FY2023 (FY) 2023-12-31 $69.9M -$24.7M -$21.6M -$21.6M β€” β€”

3. ACTU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACTU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Actuate Therapeutics Inc. (NASDAQ: ACTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.34 (+2.06% 1D, market cap $18.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ACTU ranks #609 in composite RQD confidence.

How does ACTU compare to KYNB and AKTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACTU carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, ACTU leads on earnings multiple (N/A) while ACTU leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACTU?

Per ACTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652935), Actuate Therapeutics Inc. generated $63.0M in revenue (-10.6% YoY), -$22.2M in net income, and -$19.2M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACTU trading relative to its 50-day, 200-day, and 52-week technical levels?

ACTU last traded at $0.34 (+2.06% on volume of 295,536 shares), positioning the stock -60.92% below its 50-day simple moving average ($0.87) and -83.89% below its 200-day simple moving average ($2.11). Across its 52-week range of $0.33 to $7.90, ACTU sits at the 0.1% percentile with a 14-day RSI of 33.3 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $0.38).

Direct Sub-Reports: ACTU RQD Cockpit ACTU 12M Forecast ACTU Earnings & Move ACTU Dividends & DRIP ACTU Insiders & 13F ACTU Whale Options ACTU Profit Sankey ACTU News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

ACTU β€” Actuate Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Actuate Therapeutics Inc. (ACTU) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.34 (+2.06% 1D, market capitalization $18.4M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Actuate Therapeutics Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry,. The FY 2025 and FY 2024 revenue figures are reported as β€”, and the company's model of monetization is not detailed in the sources.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Actuate Therapeutics Inc. (ACTU) reported $63.0M in annual revenue (up from $70.5M in FY2024, -10.6% YoY) and -$22.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($69.9M revenue, -$24.7M net income) through FY2025, ACTU scaled operating cash flow to -$19.2M and free cash flow to -$19.2M, backed by $14.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.33 – $7.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be identified from the source data. A prospective investor should note that the absence of mapped links means second-order bottlenecks cannot be assessed here, and any ripple analysis would require information outside this source set.

  • Key Question #1: Can ACTU sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $63.0M and free cash flow of -$19.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ACTU's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ACTU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Actuate Therapeutics Inc. (ACTU) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ACTU Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACTU Bull vs. Bear Conversation Board β€” What's Your Call at $0.34?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACTU 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ACTU:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $0.44 (+29.4%)
πŸ“Œ Pinned Debate

Recent financings priced an $11.0 Million underwritten offering and a $9.96 Million stock-and-warrant raise, which bolster the cash bal

Picked up a starter position in ACTU in my $100K Virtual Cash book at $0.34. Recent financings priced an $11.0 Million underwritten offering and a $9.96 Million stock-and-warrant raise, which bolster the cash balance of $13.2M.. Trading inside a $0.33–$7.90 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader πŸ‚ BULL

Both sides have a point here β€” ACTU's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER β€’ Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.28 (-17.6%)
Spot @ $0.34

The company reports ROIC of -35%, zero revenue, and negative free cash flow of -$19.2M, with the stock down to $0.37 from a 52-week hig

The company reports ROIC of -35%, zero revenue, and negative free cash flow of -$19.2M, with the stock down to $0.37 from a 52-week high of $7.9.. Look at the math on ACTU: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.30 before getting long.

LIVE TAPE